Inhibition of PI3K Increases Oxaliplatin Sensitivity in Cholangiocarcinoma Cells
Author Information
Author(s): Leelawat Kawin, Narong Siriluck, Udomchaiprasertkul Wandee, Leelawat Surang, Tungpradubkul Sumalee
Primary Institution: Rajavithi Hospital, Bangkok, Thailand
Hypothesis
Inhibition of PI3K or its downstream target, mTOR, may increase oxaliplatin efficacy in treating cholangiocarcinoma.
Conclusion
Targeting the PI3K pathway may improve the chemotherapeutic sensitivity of cholangiocarcinoma.
Supporting Evidence
- Oxaliplatin treatment increased phosphorylation of Akt and mTOR in cholangiocarcinoma cells.
- Combination of oxaliplatin with PI3K inhibitor LY294002 significantly increased cell death.
- LY294002 treatment resulted in a two-fold increase in the inhibition of cell proliferation with oxaliplatin.
Takeaway
This study found that blocking a specific pathway in cancer cells can make them more sensitive to a chemotherapy drug, which could help treat a difficult type of cancer.
Methodology
Cholangiocarcinoma cell lines were treated with oxaliplatin and specific inhibitors, followed by assays to measure cell proliferation and apoptosis.
Statistical Information
P-Value
0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website